SpagoPix (pegfosimer manganese / SN132D)
MRI Contrast for Cancer (Breast, Liver, Pancreas) and Endometriosis
Phase IIaActive
Key Facts
Indication
MRI Contrast for Cancer (Breast, Liver, Pancreas) and Endometriosis
Phase
Phase IIa
Status
Active
Company
About Spago Nanomedical
Spago Nanomedical is a clinical-stage company developing targeted cancer therapies and diagnostics via its patented polymeric nanoparticle platform. Key achievements include a positive DMC recommendation and proof-of-concept in its Phase I/IIa Tumorad-01 study, and clinical validation of its SpagoPix MRI agent. The company's strategy is to advance its pipeline to key inflection points before pursuing out-licensing deals with larger partners for global commercialization.
View full company profile